Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6537752 | 0.89 | ALDH1A1 (0.35) | KDM4EL3MBTL1EPHX2ALDH1A1 | |
| SCHEMBL2982384 | 0.71 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1 | |
| SCHEMBL16244843 | 0.69 | KDM4E (0.33) | KDM4EL3MBTL1EPHX2 | |
| SCHEMBL417593 | 0.63 | CYP11B2 (0.33) | KDM4EL3MBTL1 | |
| SCHEMBL2558905 | 0.61 | ESR2 (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL22447830 | 0.59 | IDO1 (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL8977432 | 0.59 | LMNA (0.36) | ALDH1A1 | |
| SCHEMBL16877327 | 0.57 | TTR (0.42) | ALDH1A1 | |
| SCHEMBL14506029 | 0.55 | — | — | |
| SCHEMBL21863882 | 0.55 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7557130-B2 | Bicyclic heteroaromatic alanines | UCB PHARMA, S.A. (BE) | 2009-07-07 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| WO-2008125210-A1 | QUINOLINE AND NAPHTHALENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN TREATMENT OF INFLAMMATORY DISEASES | UCB PHARMA, S.A. (BE) | 2008-10-23 | — | — | WO | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
| US-7122556-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | disclosed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | disclosed |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | UCB PHARMA S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| EP-1370531-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003011815-A1 | BICYCLIC HETEROAROMATIC ALANINES | CELLTECH R & D LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | KDM4E 1354/4885L3MBTL1 732/4885EPHX2 1067/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | KDM4E 1834/4885L3MBTL1 533/4885EPHX2 994/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | KDM4E 1689/4885L3MBTL1 871/4885EPHX2 851/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | KDM4E 1478/4885L3MBTL1 636/4885EPHX2 760/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | KDM4E 3394/4885L3MBTL1 1375/4885EPHX2 739/4885 |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | ICAM1, VCAM1, CCR1 | KDM4E 1601/4885L3MBTL1 1806/4885EPHX2 451/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | KDM4E 1834/4885L3MBTL1 533/4885EPHX2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.